Lamei Zhou

Lamei Zhou


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2026 in Fitoterapia
Verified
Journal Article
Closed access
YLYuanyuan Liu
Yuanyuan Liu
GZGuoqing Zhao
Guoqing Zhao
XZXiaorong Zhang
Xiaorong Zhang
YXYingxue Xiao
Yingxue Xiao
HZHao Zhi
Hao Zhi
JZJian Zhang
Jian Zhang

2 October 2025 in Immunology
Verified
Journal Article
Open access
XZXuhong Zhang
Xuhong Zhang
LJLu Jia
Lu Jia
XLXueni Lin
Xueni Lin
LZLamei Zhou
Lamei Zhou
Ankylosing spondylitis (AS) is a chronic immune‐mediated disease marked by sustained joint inflammation and aberrant bone remodelling. Although chronic antigen exposure usually enforces terminal exhaustion, emerging evidence indicates that a subset of CD8 + T cells in AS evades canonical exhaustion programmes while expressing programmed cell death protein 1 (PD‐1). These exhaustion‐resistant cells retain effector function and likely contribute to persistent tissue inflammation and structural damage. In this review, we dissect the cellular and molecular basis of exhaustion resistance in AS CD8 + T cells and focus on the convergence of intermittent T cell receptor (TCR) stimulation, metabolic adaptation that preserves mitochondrial fitness, and co‐stimulatory inputs from interleukin‐15 (IL‐15) and CD28. We propose an integrated three‐axis model governing CD8 + T cell fate and functional persistence in the AS context shaped by human leukocyte antigen‐B27 (HLA‐B27) and the gut–joint axis. Clarifying these mechanisms refines current views of T cell dysfunction in chronic inflammation and highlights therapeutic strategies aimed at reprogramming pathogenic immunity in AS.

1 December 2025 in The Analyst
Verified
Journal Article
Closed access
PDF file
FYFeng Yang
Feng Yang
CDCongying Ding
Congying Ding
ZCZihui Chen
Zihui Chen
GZGuoqing Zhao
Guoqing Zhao
LZLamei Zhou
Lamei Zhou
WYWanqing Yue
Wanqing Yue
Preparation of V-Ti 3 C 2 and its application in dye adsorption and degradation, as well as Fe 3+ detection.

18 November 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
XZXuhong Zhang
Xuhong Zhang
LJLu Jia
Lu Jia
XLXueni Lin
Xueni Lin
LZLamei Zhou
Lamei Zhou
The gut-bone axis is pivotal in the pathogenesis of ankylosing spondylitis (AS), with gut dysbiosis and mucosal immune activation driving skeletal pathology. However, translating these mechanistic insights into effective therapies remains challenging. This review critically analyzes this translational gap, arguing that the therapeutic paradoxes seen with cytokine inhibitors and microbiome-targeted therapies are a direct consequence of the disease's significant variability. We focus on the unexpected failure of IL-23 inhibitors and the dual effects of IL-17 blockade to illustrate the need for a nuanced understanding of tissue-specific immunity. We then propose a biomarker-driven, AI-assisted therapeutic framework that integrates multi-omic data to personalize AS treatment, aiming to bridge the gap between mechanistic insights and clinical success and offer a path toward progression-free remission.

26 December 2024 in Heliyon
Verified
Journal Article
Open access
FZFenglin Zhu
Fenglin Zhu
MWMiao Wang
Miao Wang
XZXuhong Zhang
Xuhong Zhang
GZGuoqing Zhao
Guoqing Zhao
HGHongyan Gao
Hongyan Gao
LZLamei Zhou
Lamei Zhou
Rheumatoid arthritis (RA) is associated with a high rate of hepatitis B virus (HBV) infection. A large proportion of HBV reactivation may occur in RA patients after immunosuppression treatment, while fulminant hepatitis may occur in severe cases. Immunosuppressants are fundamental medications for the treatment of RA but carry the risk of inducing HBV reactivation. This inherent contradiction poses challenges throughout the immunosuppressive treatment process in patients with RA. Recently, numerous studies have been conducted on the contradictory therapeutic mechanisms between RA treatment and HBV infection, including aspects of innate immunity, adaptive immunity, and related signalling pathways. In this article, we review the immunological mechanisms underlying the onset of RA and HBV infections, providing a reference for determining appropriate treatment plans to reduce therapeutic contradictions and thereby reduce the risk of HBV reactivation in patients with RA combined with HBV infection.